February 15, 2017

BioCanRX makes a major investment in Canadian biotherapeutics research

 

CAT-T

Biotherapeutics, a relatively new class of treatments, have shown great promise and are generating a lot of excitement in the cancer research community. These treatments harness the power of oncolytic viruses, cell therapies and antibodies to kill cancer. BioCanRX, Canada’s biotherapeutics research network, has announced $11 million in funding for 16 projects that will enable scientists across the country to bring their innovations to patients sooner.

Continue reading – BioCanRX makes a major investment in Canadian biotherapeutics research

October 21, 2016

OICR-led study finds four unique genomic signatures in pancreas cancer, uncovers potential of immunotherapies

The pancreas cancer puzzle

Pancreas cancer is one of the most aggressive and deadly forms of the disease. According to the Canadian Cancer Society, only 8 percent of pancreas cancer patients survive more than five years after diagnosis. OICR’s PanCuRx Translational Research Initiative has recently published the results of an international collaboration that increases understanding of this complex disease and how to treat it based on a patient’s unique profile.

Continue reading – OICR-led study finds four unique genomic signatures in pancreas cancer, uncovers potential of immunotherapies